LUPINNSELupin Limited· PharmaceuticalsMinimalNeutral
Announced Sat, 9 May · 13:32 IST

Lupin Limited has informed the Exchange regarding Copy of Newspaper Publication regarding Audited Financial Results of the Company for the quarter and year ended March 31, 2026

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.1%1-day move
₹2373.00
prior close
₹2330.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.0-1.5-1.3-3.4-5.1-6.4-5.1-3.8-5.0-3.8-5.1-4.2+4.8
Up moveDown movePending
AI summary

Lupin Limited has published its audited financial results for Q4 and FY2025-26. Consolidated revenue for FY26 stood at Rs 279,580.3 million, up 23% from Rs 227,079.0 million in FY25. Net profit after tax (consolidated) grew significantly to Rs 53,554.7 million, a 62% increase year-on-year. For Q4 alone, revenue was Rs 74,746.6 million (up 8.7% QoQ) and PAT was Rs 14,686.7 million. Standalone revenue from operations was Rs 195,126.6 million for FY26, up 15% from prior year. The Board has recommended a final dividend of Rs 7.75 per equity share (face value Rs 2 each), subject to shareholder approval at the AGM.

Likely market impact

Strong financial performance with revenue and profit growing in double digits demonstrates robust operational performance. The recommended dividend provides direct return to shareholders. Overall positive for stock price.